NCT04695769View on ClinicalTrials.gov

Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

PHASE4CompletedINTERVENTIONAL
Enrollment

281

Participants

Timeline

Start Date

November 21, 2020

Primary Completion Date

October 21, 2021

Study Completion Date

October 21, 2021

Conditions
Chronic Hepatitis C
Interventions
DRUG

Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi] plus Ribavirin

Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir with weight-based Ribavirin for 12 weeks.

DRUG

Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

Patients will receive Sofosbuvir / Velpatasvir / Voxilaprevir for 12 weeks.

Trial Locations (1)

Unknown

Faculty of medicine Helwan University, Cairo

All Listed Sponsors
lead

Helwan University

OTHER

NCT04695769 - Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders | Biotech Hunter | Biotech Hunter